Breast Cancer

Pamidronate prevents chemotherapy-induced bone loss in premenopausal women

Published in Cancer Weekly, July 19th, 2005

Pamidronate prevents chemotherapy-induced bone loss in premenopausal women, researchers report.

"Mortality from breast cancer has decreased in large part because of adjuvant chemotherapy. Sequelae of therapy include ovarian failure and bone loss - loss that would increase these patients' risk of fracture with aging," wrote G.E.H. Fuleihan and colleagues, American University of Beirut, who conducted a study of "the efficacy of pamidronate in preventing such loss."

"The study was a 1-year randomized, double-blind, placebo-controlled trial comparing pamidronate 60 mg intravenously every 3 months with placebo in 40 premenopausal women with newly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-07-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry